CTSG and breast carcinoma: In a study assessing 224 cases of neuroendocrine-differentiated breast cancer, Lai et al. demonstrated that a lower level of expression of the neuroendocrine markers CG, SYN, or CD56 was correlated with decreased overall survival and higher rates of recurrence [25].